UPDATE: Teva Pharma (TEVA) Tops Q4 EPS by 1c, Offers FY20 Guidance

(Updated - February 12, 2020 7:05 AM EST)

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.62, $0.01 better than the analyst estimate of $0.61. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.35 billion.

2020 business outlook:

Revenues are expected to be $16.6 - $17.0 billion
Non-GAAP EPS is expected to be $2.30 - $2.55
Free cash flow is expected to be $1.8 - $2.2 billion

(*consensus sees FY20 EPS of $2.47 on revenue of $17.2 billion)

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• General Motors (GM) Tops Q1 EPS by 50c, Raises Guidance
• First Bancorp. (FBP) Tops Q1 EPS by 7c